10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Thursday. Shares of…
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain cancers, China granted Summit the marketing authorization.
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday. Shares of Stericycle,…
Summit Therapeutics Raised $200M Via Institutional Offering of 22.2M Shares at $9/Share for Clinical Development of Ivonescimab, To Expand License Territories for Ivonescimab
Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to
Summit Therapeutics Ivonescimab In Combination with Chemotherapy Approved In China By NMPA For 2L+ EGFRm NSCLC Based On HARMONi-A Clinical Trial; Clinically Meaningful Efficacy Observed In Overall Survival Towards Ivonescimab Plus Chemotherapy; Shares…
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46For Subset of Patients Previously Receiving 3rd Generation
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday’s session after the company posted mixed first-quarter results.…
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday’s regular session. The company’s market cap…
Summit Therapeutics’ Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck’s Multi-Billion Keytruda In China Study
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly improved progression-free survival in NSCLC patients compared to Keytruda.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock moved upwards by 69.6% to $0.77 during Friday’s pre-market session. The company’s…